Ixodes Salivary Gland Polypeptide for Brain Inflammation Without Bleeding Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for intracerebral hemorrhage (ICH) are limited, and there is an unmet need for agents that can prevent or treat brain inflammation without exacerbating the hemorrhage, as existing therapies often worsen outcomes due to increased bleeding risk.
Innovation Solution
A protein or polypeptide with at least 95% sequence identity to SEQ ID NO: 1, derived from Ixodes ricinus salivary gland, is administered to prevent or treat brain inflammation by reducing neuroinflammation, without increasing hemorrhage or edema volume.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional therapies are used to treat brain inflammation after ICH, then inflammatory response may be reduced, but hemorrhage volume increases and clinical outcomes worsen
Solution Approach 1:
The patent uses a specific polypeptide (Ir-CPI) derived from Ixodes ricinus salivary gland as an intermediary substance that mediates between the conflicting needs of reducing inflammation and preventing hemorrhage expansion. This polypeptide acts as a selective inhibitor that targets inflammatory pathways (particularly neutrophil infiltration and activation) without affecting hemostatic mechanisms, thus resolving the contradiction by introducing a specialized mediator that can distinguish between inflammatory and hemostatic processes.
Solution Approach 2:
The invention changes the therapeutic parameter from non-specific anti-inflammatory agents to a highly specific polypeptide with defined molecular characteristics (amino acid sequence identity ≥95% to SEQ ID NO: 1). This parameter change enables selective inhibition of inflammatory responses while preserving hemostatic function, thereby reducing brain inflammation without causing hemorrhage expansion.
2Object-affected harmful factors
If anti-inflammatory agents are administered to reduce neuroinflammation, then secondary brain injury may be reduced, but bleeding risk increases
Solution Approach 1:
The polypeptide Ir-CPI serves as a selective intermediary that targets inflammatory cells (neutrophils, microglia) through specific molecular interactions (likely involving chemokine receptors or adhesion molecules) without interfering with platelet function or coagulation cascades. This selectivity allows the agent to reduce neuroinflammation while maintaining normal hemostatic responses, thereby reducing bleeding risk compared to conventional anti-inflammatory drugs.
Solution Approach 2:
The patent applies the principle of local quality by designing a polypeptide that exhibits selective action in the brain tissue environment. The Ir-CPI polypeptide demonstrates preferential binding or interaction with inflammatory cells in the cerebral parenchyma while having minimal effect on systemic hemostatic mechanisms, thus achieving local anti-inflammatory effects without compromising overall bleeding risk.
3Reliability
If treatment is delayed after brain injury, then hemorrhage stabilization may be achieved, but inflammatory damage increases
Solution Approach 1:
The patent enables preliminary action by allowing administration of the Ir-CPI polypeptide within a narrow therapeutic window (early after ICH onset) when both hemorrhage stabilization and inflammation control are critical. The polypeptide's rapid onset of action and selective mechanism allow it to be administered before inflammatory damage becomes irreversible, while simultaneously providing hemorrhage stabilization through its anti-inflammatory effects that prevent secondary injury.
Data Source
Figure 1A~1D
Figure 2A~2C
Figure 3
AI summary
The present invention relates to proteins and polypeptides from the salivary gland of Ixodes ricinus for their use for preventing and/or treating brain inflammation and diseases or conditions associated with brain inflammation, and methods for preventing and/or treating brain inflammation and diseases or conditions associated with brain inflammation. The polypeptides are further used to prevent, reduce, decrease or inhibit neuronal death.